A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.

Détails

ID Serval
serval:BIB_0413829B2C88
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.
Périodique
Clinical Oncology (Royal College of Radiologists (Great Britain))
Auteur(s)
León X., Hitt R., Constenla M., Rocca A., Stupp R., Kovács A.F., Amellal N., Bessa E.H., Bourhis J.
ISSN
0936-6555
Statut éditorial
Publié
Date de publication
09/2005
Peer-reviewed
Oui
Volume
17
Numéro
6
Pages
418-424
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Résumé
AIMS: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) develops in around 72,000 people in Europe every year. Treatment options are limited, mainly consisting of platinum-based palliative chemotherapy, with median overall survival times of only 6-8 months. No standard second-line treatment after progression on platinum-based chemotherapy is available. Few data have reported the efficacy of these treatments and the outcome of the patients. In an effort to generate such data, this retrospective study analysed clinical records from 151 patients with SCCHN refractory to platinum-based chemotherapy treated between 1990 and 2000 at seven different centres around Europe. MATERIALS AND METHODS: Most patients (45%) received only best supportive care (BSC), and had a median survival of 56 days. A total of 28.5% of the patients received second-line chemotherapies: 16.6% radiotherapy and 9.9% chemoradiotherapy. RESULTS: No objective response was observed with the various second-line chemotherapies. The overall median survival was 103 days (95% confidence interval [CI]: 77-126 days) for the whole cohort. The overall objective response rate (ORR) to second-line treatment in this population was calculated to be 2.6%. CONCLUSION: These results highlight the need for additional treatment options for this disease. Similar, if not superior, response rates have already been observed in initial clinical studies of novel, targeted anti-cancer agents.
Mots-clé
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Squamous Cell/drug therapy, Carcinoma, Squamous Cell/secondary, Female, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/pathology, Humans, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Neoplasm Staging, Organoplatinum Compounds/therapeutic use, Retrospective Studies, Salvage Therapy, Survival Rate, Treatment Outcome
Pubmed
Web of science
Création de la notice
28/01/2008 9:39
Dernière modification de la notice
03/03/2018 13:21
Données d'usage